PTH and secondary hyperparathyroidism: Targeting CaSR in the parathyroid gland by the FDA-approved drug cinacalcet or other calcimimetics suppresses parathyroid hormone (PTH) secretion, which is commonly used to treat secondary hyperparathyroidism associated with chronic kidney disease or renal failure.